Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alize Pharma 3 Announces Rebranding to Amolyt Pharma
Details : Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
